Relationship of psychopathological symptoms and cognitive function to subjective quality of life in patients with chronic schizophrenia

Psychiatry and Clinical Neurosciences

Volumn 64, Issue 1, 2010, Pages 62-69

  Tomida, Kenji ^a   Takahashi, Nagahide ^b   Saito, Shinichi ^a,c   Maeno, Nobuhisa ^a,d   Iwamoto, Kunihiro ^a   Yoshida, Keizo ^a   Kimura, Hiroyuki ^a   Iidaka, Tetsuya ^a   Ozaki, Norio ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Matsusaka General Hospital   (Japan)

^d NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Cognition; Positive and negative syndrome scale; Quality of life; Regression analysis; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; ANXIETY; ARTICLE; COGNITION; DEPRESSION; ENERGY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTIVATION; PATIENT SATISFACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; QUALITY OF LIFE; SCHIZOPHRENIA; SOCIAL PSYCHOLOGY; SYMPTOM;

ADULT; ANXIETY; ATTENTION; CHRONIC DISEASE; COGNITION; DEPRESSION; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTIVATION; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; REGRESSION ANALYSIS; SCHIZOPHRENIC PSYCHOLOGY;

EID: 75649139099     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2009.02033.x     Document Type: Article

References (43)

1. Revicki DA, Murray M. Assessing health-related quality of life outcomes of drug treatments for psychiatric disorders. CNS Drugs 1994 1 : 465 476.
2. Dobre D, van Jaarsveld CH, deJongste MJ, Haaijer Ruskamp FM, Ranchor AV. The effect of beta-blocker therapy on quality of life in heart failure patients: A systematic review and meta-analysis. Pharmacoepidemiol. Drug Saf. 2007 16 : 152 159.
3. Browne S, Roe M, Lane A et al. Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr. Scand. 1996 94 : 118 124.
4. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984 10 : 388 398.
5. Skantze K, Malm U, Dencker SJ, May PR, Corrigan P. Comparison of quality of life with standard of living in schizophrenic out-patients. Br. J. Psychiatry 1992 161 : 797 801.
6. Lehman AF. The effects of psychiatric symptoms on quality of life assessments among the chronic mentally ill. Eval. Program Plann. 1983 6 : 143 151.
7. Lehman AF. The well-being of chronic mental patients. Arch. Gen. Psychiatry 1983 40 : 369 373.
8. Awad AG, Voruganti LN, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: Description and preliminary clinical validation. Qual. Life Res. 1997 6 : 21 26.
9. Wilkinson G, Hesdon B, Wild D et al. Self-report quality of life measure for people with schizophrenia: The SQLS. Br. J. Psychiatry 2000 177 : 42 46.
10. Kaneda Y, Imakura A, Fujii A, Ohmori T. Schizophrenia Quality of Life Scale: Validation of the Japanese version. Psychiatry Res. 2002 113 : 107 113.
11. Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. Quality of life in schizophrenia: The impact of psychopathology, attitude toward medication, and side effects. J. Clin. Psychiatry 2004 65 : 932 939.
12. Karow A, Moritz S, Lambert M, Schoder S, Krausz M. PANSS syndromes and quality of life in schizophrenia. Psychopathology 2005 38 : 320 326.
13. Kugo A, Terada S, Ishizu H et al. Quality of life for patients with schizophrenia in a Japanese psychiatric hospital. Psychiatry. Res. 2006 144 : 49 56.
14. Norman RM, Malla AK, McLean T et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr. Scand. 2000 102 : 303 309.
15. Gaite L, Vazquez-Barquero JL, Borra C et al. Quality of life in patients with schizophrenia in five European countries: The EPSILON study. Acta Psychiatr. Scand. 2002 105 : 283 292. (Pubitemid 34275846)
16. Ho BC, Nopoulos P, Flaum M, Arndt S, Andreasen NC. Two-year outcome in first-episode schizophrenia: Predictive value of symptoms for quality of life. Am. J. Psychiatry 1998 155 : 1196 1201.
17. Packer S, Husted J, Cohen S, Tomlinson G. Psychopathology and quality of life in schizophrenia. J. Psychiatry Neurosci. 1997 22 : 231 234.
18. Lewis R. Should cognitive deficit be a diagnostic criterion for schizophrenia? J. Psychiatry Neurosci. 2004 29 : 102 113.
19. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 1996 153 : 321 330.
20. Heinrichs RW. Meta-analysis and the science of schizophrenia: Variant evidence or evidence of variants? Neurosci. Biobehav. Rev. 2004 28 : 379 394.
21. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol. Psychiatry 1994 36 : 717 725.
22. Matsui M, Sumiyoshi T, Arai H, Higuchi Y, Kurachi M. Cognitive functioning related to quality of life in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008 32 : 280 287.
23. Meltzer HY, Thompson PA, Lee MA, Ranjan R. Neuropsychologic deficits in schizophrenia: Relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology 1996 14 : 27S 33S.
24. Wegener S, Redoblado-Hodge MA, Lucas S, Fitzgerald D, Harris A, Brennan J. Relative contributions of psychiatric symptoms and neuropsychological functioning to quality of life in first-episode psychosis. Aust. N. Z. J. Psychiatry 2005 39 : 487 492.
25. Addington J, Addington D. Neurocognitive and social functioning in schizophrenia. Schizophr. Bull. 1999 25 : 173 182.
26. Aksaray G, Oflu S, Kaptanoglu C, Bal C. Neurocognitive deficits and quality of life in outpatients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002 26 : 1217 1219.
27. Heslegrave RJ, Awad AG, Voruganti LN. The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. J. Psychiatry Neurosci. 1997 22 : 235 243.
28. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, DC, 1994.
29. Inagaki A, Inada T, Fujii A et al. Equivalent Doses of Psychotropic Drugs. Seiwa shoten, Tokyo, 1999.
30. Hofer A, Baumgartner S, Bodner T et al. Patient outcomes in schizophrenia II: The impact of cognition. Eur. Psychiatry 2005 20 : 395 402.
31. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987 13 : 261 276.
32. Lindenmayer JP, Bernstein-Hyman R, Grochowski S. Five-factor model of schizophrenia. Initial validation. J. Nerv. Ment. Dis. 1994 182 : 631 638.
33. Lindenmayer JP, Grochowski S, Hyman RB. Five factor model of schizophrenia: Replication across samples. Schizophr. Res. 1995 14 : 229 234.
34. Kashima H, Kato M. Tests for frontal function-pattern of frontal dysfunction and its assessment. Shinkei Kenkyu No Shimpo 1993 37 : 93 110 (in Japanese).
35. Kobayashi S. Wisconsin Card Sorting Test (WCST). Nippon Rinsho 2003 61 (Suppl. 9 344 349 (in Japanese).
36. Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L. The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res. 1988 26 : 223 238.
37. Meltzer HY, Burnett S, Bastani B, Ramirez LF. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp. Community Psychiatry 1990 41 : 892 897.
38. Ginsberg DL, Schooler NR, Buckley PF, Harvey PD, Weiden PJ. Optimizing treatment of schizophrenia. Enhancing affective/cognitive and depressive functioning. CNS Spectr. 2005 10 : 1 15.
39. Taniguchi T, Sumitani S, Aono M et al. Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms. Hum. Psychopharmacol. 2006 21 : 439 445.
40. Yamauchi K, Aki H, Tomotake M et al. Predictors of subjective and objective quality of life in outpatients with schizophrenia. Psychiatry Clin. Neurosci. 2008 62 : 404 411.
41. The WHOQoL Group. Development of the World Health Organization WHOQoL-BREF quality of life assessment. Psychol. Med. 1998 28 : 551 558.
42. Cornblatt BA, Winters L, Erlenmeyer-Kimling L. Attentional markers of schizophrenia: Evidence from the New York High Risk Study. In : Schulz SC, Tamminga CA (eds). Schizophrenia: Scientific Progress. Oxford University Press, New York, 1989 83 92.
43. Prouteau A, Verdoux H, Briand C et al. Cognitive predictors of psychosocial functioning outcome in schizophrenia: A follow-up study of subjects participating in a rehabilitation program. Schizophr. Res. 2005 77 : 343 353.